Multiplexed Protein Measurement by Real-time Immuno-PCR

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$978,045.00
Award Year:
2006
Program:
SBIR
Phase:
Phase II
Contract:
2R44HG003508-02
Award Id:
70878
Agency Tracking Number:
HG003508
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
AMPLIFIED PROTEOMICS, INC, 2462 WYANDOTTE ST, MOUNTAIN VIEW, CA, 94043
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
HUANGTSU CHEN
() -
Business Contact:
ERIC HOANG
(650) 504-0376
HETETH75@YAHOO.COM
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Numerous proteomics platforms for measuring multiple proteins in parallel have been developed, but adoption has been limited by the fact that they all are orders of magnitude less sensitive than standard ELISA assays. By contrast, methods for quantitatively measuring the levels of multiple mRNAs in parallel are very robust and sensitive. The real-time polymerase chain reaction (PCR) is the most sensitive and commonly used method for quantitative gene expression profiling; it allows extremely sensitive measurement of hundreds of mRNA transcripts in parallel. We have now developed a proprietary method for using the real-time-PCR technology to measure protein concentrations, also in a multiplexed fashion and with very high sensitivity and reproducibility. The method, Multiplexed Real-time-lmmuno-PCR (MRI-PCR), consists of a sandwich immuno-assay in which the detection antibodies are labeled with different DMA sequences. Real-time PCR is then used to quantify all of the DNA labels in parallel, thus revealing the quantities of the cognate proteins in the biological samples. Phase I data show that multiplexed protein measurements employing MRI-PCR assays provides about 2 orders of magnitude more sensitive detection and >2 orders of magnitude increased dynamic range in comparison to standard ELISA assays, along with very low standard deviations (CV <10%) and high specificity. In Phase II, we propose to develop two commercial-ready panels of dodecaplexed assays for 12 cytokines and 12 adipokines, targeting research needs in inflammatory and metabolic diseases, respectively.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government